Article in Disease models & mechanisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Latifa BakiriLaboratory Genes and Disease, Department of Laboratory Medicine, Medical University of Vienna, Vienna (MUW), Spitalgasse 23, 1090 Vienna, Austria.ORCID 0000-0002-6300-2420
Mélanie TichetLudwig Institute for Cancer Research, Lausanne Branch; Swiss Institute for Experimental Cancer Research (ISREC), EPFL; Swiss Cancer Center Leman (SCCL); Agora Translational Cancer Research Center, Rue du Bugnon 25A, 1005 Lausanne, Switzerland.ORCID 0000-0001-7128-4061
Carolina MarquesSeve Ballesteros Foundation Brain Tumor Group, Spanish National Cancer Research Centre, Melchor Fernández Almagro, 3, 28029 Madrid, Spain.
Martin K ThomsenDepartment of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, 8000 Aarhus, Denmark.ORCID 0000-0002-5055-7531
Elizabeth A AllenLudwig Institute for Cancer Research, Lausanne Branch; Swiss Institute for Experimental Cancer Research (ISREC), EPFL; Swiss Cancer Center Leman (SCCL); Agora Translational Cancer Research Center, Rue du Bugnon 25A, 1005 Lausanne, Switzerland.
Stefanie StolzlechnerLaboratory Bone Cancer Metastasis, Cellular and Molecular Tumor Biology, Center for Cancer Research, Medical University of Vienna (MUW), Spitalgasse 23, 1090 Vienna, Austria.ORCID 0000-0001-8001-3909
Ke ChengLudwig Institute for Cancer Research, Lausanne Branch; Swiss Institute for Experimental Cancer Research (ISREC), EPFL; Swiss Cancer Center Leman (SCCL); Agora Translational Cancer Research Center, Rue du Bugnon 25A, 1005 Lausanne, Switzerland.
Kazuhiko MatsuokaLaboratory Bone Cancer Metastasis, Cellular and Molecular Tumor Biology, Center for Cancer Research, Medical University of Vienna (MUW), Spitalgasse 23, 1090 Vienna, Austria.ORCID 0000-0001-8982-5399
Massimo SquatritoSeve Ballesteros Foundation Brain Tumor Group, Spanish National Cancer Research Centre, Melchor Fernández Almagro, 3, 28029 Madrid, Spain.ORCID 0000-0002-4593-3790
Douglas HanahanLudwig Institute for Cancer Research, Lausanne Branch; Swiss Institute for Experimental Cancer Research (ISREC), EPFL; Swiss Cancer Center Leman (SCCL); Agora Translational Cancer Research Center, Rue du Bugnon 25A, 1005 Lausanne, Switzerland.ORCID 0000-0002-0883-5251
Erwin F WagnerLaboratory Genes and Disease, Department of Laboratory Medicine, Medical University of Vienna, Vienna (MUW), Spitalgasse 23, 1090 Vienna, Austria.ORCID 0000-0001-7872-0196
Funding
European Research Council AdG-741888-CSI-Fun, AdG-322491-HALLMARKS-TO-THERAPYH2020 European Research Council AdG-322491-HALLMARKS-TO-THERAPYH2020 European Research Council AdG-741888-CSI-FunH2020 European Research Council AdG-834947-CAN-IT-BARRIERSH2020 Marie Skodowska-Curie Actions ITN-859860-CANCERPREVHorizon Europe Marie Sklodowska-Curie Actions ITN-859860-CANCERPREVLudwig Institute for Cancer ResearchMedizinische Universität Wien
6 · The paper itself
Abstract
Genetically engineered mouse models (GEMMs) are instrumental for modelling local and systemic features of complex diseases, such as cancer. Non-invasive, longitudinal cell detection and monitoring in tumors, metastases and/or the micro-environment is paramount to achieve a better spatiotemporal understanding of cancer progression and to evaluate therapies in preclinical studies. Bioluminescent and fluorescent reporters marking tumor cells or their microenvironment are valuable for non-invasive cell detection and monitoring in vivo. Here, we report the generation of a dual reporter allele allowing simultaneous bioluminescence and fluorescence detection of cells that have undergone Cre-Lox recombination in mice. The single copy knock-in allele in the permissive collagen I locus was evaluated in the context of several cancer GEMMs, where Cre expression was achieved genetically or by ectopic virus-mediated delivery. The new reporter allele was also combined with gene-targeted alleles widely used in bone, prostate, brain and pancreas cancer research, as well as with alleles inserted into the commonly used Rosa26 and collagen I loci. This allele is, therefore, a useful addition to the portfolio of reporters to help advance preclinical research.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A new effLuc/Kate dual reporter allele for tumor imaging in mice. · full record | OpenQuestion